<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03178669</url>
  </required_header>
  <id_info>
    <org_study_id>CSUC-01/16</org_study_id>
    <secondary_id>2016-004217-26</secondary_id>
    <nct_id>NCT03178669</nct_id>
  </id_info>
  <brief_title>The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis</brief_title>
  <acronym>CONDUCT</acronym>
  <official_title>A Randomised Dose-Optimisation Study to Evaluate the Efficacy and Safety of Cobitolimod in Moderate to Severe Active Ulcerative Colitis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InDex Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InDex Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy of cobitolimod treatment at different dose
      levels and frequencies compared to placebo in patients with moderate to severe active
      ulcerative colitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2b study in patients with moderate to severe active ulcerative colitis.
      Patients will either receive cobitolimod dose A, B or C at two occasions or dose B or placebo
      at four occasions. To ensure blindness patients receiving active treatment at two occasions
      will receive placebo at the other two occasions. Blood, stool, and tissue samples will be
      collected at various time points throughout the study to evaluate safety and efficacy.

      Duration of participation for patients will be approximately 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 21, 2017</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Remission</measure>
    <time_frame>6 weeks after first treatment</time_frame>
    <description>defined by Modified Mayo sub scores, i) rectal bleeding of 0, ii) stool frequency of 0 or 1 (with at least one point decrease from Baseline, and iii) endoscopy score of 0 or 1 (excluding friability)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptomatic Remission</measure>
    <time_frame>Week 4 and Week 6</time_frame>
    <description>defined by the Mayo sub scores, i) rectal bleeding of 0, ii) stool frequency of 0 or 1 (with at least one point decrease from Baseline, (patient reported outcome) [PRO2]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abscence of rectal bleeding</measure>
    <time_frame>Week 4 and Week 6</time_frame>
    <description>defined by the Mayo sub score rectal bleeding of 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normal or enhanced stool frequency</measure>
    <time_frame>Week 4 and Week 6</time_frame>
    <description>defined by the Mayo sub score stool frequency of 0 or 1 (with at least one point decrease from Baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic Remission</measure>
    <time_frame>Week 6</time_frame>
    <description>defined by the Modified Mayo endoscopic sub score of 0 or 1 (excluding friability)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological Remission</measure>
    <time_frame>Week 6</time_frame>
    <description>defined by the Nancy histological index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological Response</measure>
    <time_frame>Week 6</time_frame>
    <description>defined by the Nancy histological index score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Clinical Remission</measure>
    <time_frame>Week 6</time_frame>
    <description>defined by the Modified Mayo score ≤ 2 and sub scores, i) rectal bleeding of 0, ii) stool frequency of 0 or 1 (with at least one point decrease from Baseline), iii) endoscopy score of 0 or 1 (excluding friability ) and iiii) physician´s global assessment (PGA) of 0 or 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response</measure>
    <time_frame>Week 6</time_frame>
    <description>defined as clinical remission or a three point and ≥ 30% decrease from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in faecal calprotectin</measure>
    <time_frame>Week 1,2, 3 and 6</time_frame>
    <description>defined as a mean change compared to Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the inflammatory bowel disease questionnaire (IBDQ)</measure>
    <time_frame>Week 6</time_frame>
    <description>defined as mean change compared to Baseline</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">215</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Cobitolimod Dose 31 mg x 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 31 mg of cobitolimod at 2 occasions, placebo at 2 occasions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cobitolimod Dose 125 mg x 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 125 mg of cobitolimod at 2 occasions, placebo at 2 occasions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cobitolimod Dose 250 mg x 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 250 mg of cobitolimod at 2 occasions, placebo at 2 occasions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cobitolimod Dose 125 mg x 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 125 mg of cobitolimod, at 4 occasions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo at four occasions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cobitolimod</intervention_name>
    <description>Rectal administration</description>
    <arm_group_label>Cobitolimod Dose 31 mg x 2</arm_group_label>
    <arm_group_label>Cobitolimod Dose 125 mg x 2</arm_group_label>
    <arm_group_label>Cobitolimod Dose 250 mg x 2</arm_group_label>
    <arm_group_label>Cobitolimod Dose 125 mg x 4</arm_group_label>
    <other_name>Kappaproct</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solution manufactured to mimic cobitolimod</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo (for cobitolimod)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old

          -  Established diagnosis of UC

          -  Moderately to severely active left sided UC assessed by central reading

          -  Current oral 5-ASA/SP use or a history of oral 5-ASA/SP use

          -  Current GCS use or history of GCS dependency, refractory, or intolerance

          -  Demonstrated an inadequate response, loss of response, or intolerance to at least one
             of the following agents:

               -  Immunomodulators

               -  TNF-α inhibitors and/or anti-integrins

        Exclusion Criteria:

          -  Suspicion of differential diagnosis

          -  Acute fulminant UC and/or signs of systemic toxicity

          -  UC limited to the rectum (disease which extend &lt;15 cm above the anal verge)

          -  History of malignancy

          -  History or presence of any clinically significant disorder

          -  Concomitant treatment with cyclosporine, methotrexate, tacrolimus, TNF-α inhibitors,
             anti-integrins or similar immunosuppressants and immunomodulators

          -  Treatment with rectal GCS, 5-ASA/SP or tacrolimus

          -  Long term treatment with antibiotics or non-steroidal anti-inflammatory drugs (NSAIDs)

          -  Serious active infection

          -  Gastrointestinal infections

          -  Currently receiving parenteral nutrition or blood transfusions

          -  Females who are lactating or have a positive serum pregnancy test

          -  Women of childbearing potential not using reliable contraceptive methods

          -  Concurrent participation in another clinical study

          -  Previous exposure to cobitolimod
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raja Atreya</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friedrich-Alexander University Erlangen-Nuremberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>InDex Pharmaceuticals</last_name>
    <phone>+46 8 508 847 30</phone>
    <email>info@indexpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karin Arnesson</last_name>
    <phone>+46 8 508 847 34</phone>
    <email>karin.arnesson@indexpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>1</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>2</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>3</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>4</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>5</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>6</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>7</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>8</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>9</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>10</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>11</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>12</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>13</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>14</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>15</name>
      <address>
        <city>Hanover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>16</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>17</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>18</name>
      <address>
        <city>Lüneburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>19</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>20</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>21</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>22</name>
      <address>
        <city>Békéscsaba</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>23</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>24</name>
      <address>
        <city>Mosonmagyarovar</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>25</name>
      <address>
        <city>Pécs</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>26</name>
      <address>
        <city>Czestochowa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>27</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>28</name>
      <address>
        <city>Ksawerów</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>29</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>30</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>31</name>
      <address>
        <city>Sopot</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>32</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>33</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>32</name>
      <address>
        <city>Włocławek</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>33</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>34</name>
      <address>
        <city>Cheboksary</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>35</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>36</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>37</name>
      <address>
        <city>Kirov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>38</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>39</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>40</name>
      <address>
        <city>Ryazan'</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>41</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>42</name>
      <address>
        <city>Stavropol'</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>43</name>
      <address>
        <city>Tver</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>44</name>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>45</name>
      <address>
        <city>Belgrad</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>46</name>
      <address>
        <city>Ferrol</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>47</name>
      <address>
        <city>Fuenlabrada</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>48</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>49</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>50</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>51</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>52</name>
      <address>
        <city>Chernivtsi</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>53</name>
      <address>
        <city>Dnipropetrovs'k</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>54</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>55</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>56</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>57</name>
      <address>
        <city>Luts'k</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>58</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>59</name>
      <address>
        <city>Odesa</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>60</name>
      <address>
        <city>Sumy</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>61</name>
      <address>
        <city>Zaporizhzhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>62</name>
      <address>
        <city>Úzhgorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2017</study_first_submitted>
  <study_first_submitted_qc>June 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2017</study_first_posted>
  <last_update_submitted>January 4, 2018</last_update_submitted>
  <last_update_submitted_qc>January 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colitis, Ulcerative</keyword>
  <keyword>Gastrointestinal Diseases</keyword>
  <keyword>Inflammatory Bowel Disease</keyword>
  <keyword>Immunomodulator Therapy</keyword>
  <keyword>Glucocorticoids</keyword>
  <keyword>Anti-Inflammatory Agents</keyword>
  <keyword>Therapeutic uses</keyword>
  <keyword>Kappaproct</keyword>
  <keyword>IDX0150</keyword>
  <keyword>DIMS0150</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

